The influence of growth hormone (GH) on calcium\p=n-\phosphorus metabolism and modulation of vitamin D metabolism has been demonstrated, but the mechanism remains unclear. We investigated the effect of a 6-month course of GH therapy on vitamin D and mineral metabolism in twelve GH\ x=req-\ deficient children. Before GH therapy, levels of vitamin D metabolites and other biochemistry data were within normal ranges. All patients responded to GH therapy with increased growth velocity. 1,25\x=req-\ Dihydroxyvitamin D levels increased after 1 month of treatment and remained at these higher levels, with a significant increase found at 3 months (P < 0\m=.\05), whereas 24,25-dihydroxyvitamin D levels were decreased at 1 and 3 months, the latter being a significant decrease (P < 0\m=.\05),and then returned to the baseline levels at 6 months. 25-Hydroxyvitamin D levels did not change significantly. A significant increase in serum insulin-like growth factor-I (IGF-I) levels occurred during the 6 months of treatment (1 month, P < 0\m=.\01;3 and 6 months, P < 0\m=.\001).Serum parathyroid hormone (PTH) levels decreased significantly at 3 and 6 months (3 months, P < 0\m=.\01;6 months, P < 0\m=.\05). Serum calcium and phosphorus levels did not change significantly. Significant increases were found in the urinary calcium/urinary creatinine ratio (3 and 6 months, P < 0\m=.\05) and the percent tubular reabsorption of phosphorus levels (1 and 3 months, P 0\m=.\05). 
Introduction
In early studies, growth hormone (GH) was demon¬ strated to act on mineral metabolism with an increase in intestinal calcium absorption and urinary calcium excretion, and a decrease in urinary phosphorus excretion (1) (2) (3) (4) (5) (6) . The GH has been shown to increase serum l,25-(OH)2D in these rats (7, 8) . Another study demonstrated that in hypophysectomized rats, in which renal conversion of 25-hydroxyvitamin D (250HD) to l,25-(OH)2D was markedly reduced and conversion of 250HD to 24,25- dihydroxyvitamin D (24, 25 -(OH)2D) was markedly increased, treatment with rat GH resulted in a significant increase in renal conversion of 250HD to l,25-(OH)2D and a significant decrease in conversion of 250HD to 24, 25 -(OH)2D (9) . Administration of porcine GH to pigs increased serum levels of l,25-(OH)2D (10, 11) and decreased those of 24,25-(OH)2D (10 Figure 2 Correlation between the ratio of the increases in 250HD and 24,25-(OH)2D levels at 6 months (P < 0-02).
Corning Diagnostica, Tokyo, Japan Fig. 1 . l,25-(OH)2D levels began to increase after 1 month of treatment and remained high up to 6 months, with a significant increase found at 3 months (67-0 ± 13 pg/ml, < 0-05 vs pretreatment). 24,25- (OH)2D levels decreased significantly at 3 months (2-1 ± 1-2 ng/ml, < 005), and then returned to baseline levels at 6 months. No significant variations in 250HD levels were found during GH treatment. A good correlation was found between the ratio of the increase in 250HD and 24,25-(OH)2D at 6 months (Fig. 2 ). (Fig. 3) . Serum PTH levels were decreased at 1 month and remained at low levels until 6 months, with significantly lower levels observed at 3 months (147-5 ±41-6, < 0-01) and 6 months (162-0 ± 44-7, < 0-05) (Fig. 4 ). Significant increases in serum IGF-I levels occurred during the 6 months of treatment (1 month: 339-9 ± 143-2, < 001; 3 months: 377-0 ±179-9, < 0001; 6 months:
328-3 ± 177-9, < 0-001) (Fig. 5) . The UCa/UCr ratio rose slowly after the start of treatment, and significantly higher levels were found at 3 and 6 months (0-27 ±0-16 and 0-23 ±0-09,
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-C 200-100-pre 1 3 months Figure 4 Effects of GH treatment on serum PTH levels. PTH levels were significantly decreased at 3 months (P < 001 ) and 6 months (P < 005).
and 94-9 ± 2-0%, < 0-05) and fell at 6 months even though they remained higher than before treatment (Fig. 6 ). (17, 18) , the stimulation of renal la-hydroxylase activity may, theoretically, be considered as follows. First, GH or IGF-I might act on the kidneys to increase serum phosphorus levels by increasing urinary phos¬ phorus reabsorption, and this may cause an increase in the serum PTH level which stimulates la-hydroxylase activity. However, PTH levels did not rise in our study, suggesting that it is not a PTH-mediated effect.
Secondly, GH or IGF-I might directly regulate mineral metabolism through the increased rate of bone growth, resulting in a decrease in serum phosphorus which is a stimulator of la-hydroxylase activity; however, there were no changes in serum calcium or phosphorus levels in our study. Thus, it is possible that GH or IGF-I stimulates renal la-hydroxylase activity directly. Recently, a number of animal studies have suggested that the GH-dependent increase in serum l,25-(OH)2D under conditions of dietary phosphorus deprivation is mediated by IGF-I (19, 20) , and similar results have been obtained in GH-deficient patients (21) . Data obtained in phosphorus-replete hypophysectomized rats also indicated the possible role of IGF-I in mediating the effect of GH on the renal handling of phosphorus and the production of l,25-(OH)2D (22 
